QDPR Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">QDPR Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>QDPR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Quinoid Dihydropteridine Reductase</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>5875</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q16473</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~26 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Enzyme / Oxidoreductase</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Qdpr Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Quinoid Dihydropteridine Reductase (QDPR) is a crucial enzyme in the tetrahydrobiopterin (BH4) biosynthesis pathway that catalyzes the NADH-dependent reduction of quinonoid dihydrobiopterin (qBH2) back to tetrahydrobiopterin (BH4)<sup>[1]</sup>. This enzymatic activity is essential for maintaining adequate levels of BH4, which serves as an essential cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryptophan hydroxylase (TPH)<sup>[2]</sup>. [@tetrahydrobiopterin]
...QDPR Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">QDPR Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>QDPR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Quinoid Dihydropteridine Reductase</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>5875</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q16473</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~26 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Enzyme / Oxidoreductase</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Qdpr Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Quinoid Dihydropteridine Reductase (QDPR) is a crucial enzyme in the tetrahydrobiopterin (BH4) biosynthesis pathway that catalyzes the NADH-dependent reduction of quinonoid dihydrobiopterin (qBH2) back to tetrahydrobiopterin (BH4)<sup>[1]</sup>. This enzymatic activity is essential for maintaining adequate levels of BH4, which serves as an essential cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryptophan hydroxylase (TPH)<sup>[2]</sup>. [@tetrahydrobiopterin]
Molecular Function
Catalytic Activity
QDPR catalyzes the reversible reduction of qBH2 to BH4 using NADH as the electron donor<sup>[1]</sup>. The reaction follows a ping-pong bi-bi mechanism where NADH first reduces the enzyme-bound FAD cofactor, which then transfers hydride to qBH2<sup>[3]</sup>. This catalytic cycle is essential for regenerating BH4 from the non-productive qBH2 that is spontaneously formed during the normal catalytic cycle of the aromatic amino acid hydroxylases.
BH4 Biosynthesis Pathway
BH4 is synthesized through a multi-step pathway starting from GTP. The rate-limiting enzyme is GTP cyclohydrolase I (GCH1), which produces 7,8-dihydroneopterin triphosphate. This is subsequently converted through multiple enzymatic steps to BH4. QDPR acts as a crucial recycling enzyme in this pathway, preventing the accumulation of toxic qBH2<sup>[4]</sup>.
Role in Neurotransmitter Synthesis
BH4 is an essential cofactor for:
- Phenylalanine hydroxylase (PAH): Catalyzes the hydroxylation of phenylalanine to tyrosine
- Tyrosine hydroxylase (TH): Rate-limiting step in dopamine, norepinephrine, and epinephrine synthesis
- Tryptophan hydroxylase (TPH): Rate-limiting step in serotonin (5-HT) synthesis
By maintaining BH4 levels, QDPR indirectly supports proper neurotransmitter synthesis in the central and peripheral nervous systems<sup>[2]</sup>.
Structure
QDPR adopts a classic Rossmann fold structure with a central β-sheet flanked by α-helices. The active site contains a bound FAD cofactor that is essential for catalytic activity. The enzyme exists as a homodimer in solution, with each monomer containing approximately 244 amino acids<sup>[5]</sup>.
Disease Associations
Phenylketonuria (PKU)
While mutations in the PAH gene are the primary cause of classical PKU, defects in QDPR can lead to a variant form of BH4 deficiency that presents with similar phenotypes including intellectual disability if untreated<sup>[6]</sup>.
Dopa-Responsive Dystonia (DRD)
Mutations in QDPR can impair BH4 synthesis, leading to reduced dopamine levels and manifesting as childhood-onset dystonia that shows dramatic response to levodopa therapy<sup>[7]</sup>.
Neurodegenerative Diseases
Parkinson's Disease
The BH4 pathway is implicated in Parkinson's disease pathogenesis. BH4 levels are reduced in the substantia nigra of PD patients, and QDPR activity may be affected by oxidative stress<sup>[8]</sup>. The enzyme's role in maintaining dopamine synthesis makes it a potential therapeutic target.
Alzheimer's Disease
Research suggests that BH4 may have antioxidant properties and protect against amyloid-β toxicity. QDPR dysfunction could contribute to oxidative stress in Alzheimer's disease<sup>[9]</sup>.
Multiple System Atrophy (MSA)
BH4 deficiency has been reported in MSA patients, potentially contributing to the autonomic dysfunction characteristic of this disease<sup>[10]</sup>.
Psychiatric Disorders
Given the role in serotonin and dopamine synthesis, QDPR dysfunction has been implicated in:
- Depression
- Anxiety disorders
- Bipolar disorder
Therapeutic Implications
BH4 Supplementation Therapy
For patients with QDPR deficiency, BH4 supplementation (sapropterin dihydrochloride) can be an effective treatment to restore neurotransmitter synthesis<sup>[6]</sup>.
Antioxidant Therapy
BH4 is a potent antioxidant that can scavenge [reactive oxygen species](/entities/reactive-oxygen-species) (ROS). Developing compounds that enhance QDPR activity could provide neuroprotective effects in neurodegenerative diseases<sup>[8]</sup>.
Gene Therapy
Emerging gene therapy approaches aim to deliver functional QDPR genes to restore enzymatic activity in patients with genetic deficiencies<sup>[11]</sup>.
Research Directions
Understanding QDPR in Neurodegeneration: Elucidating the precise molecular mechanisms by which QDPR dysfunction contributes to neurodegenerative processes
Biomarker Development: Identifying biomarkers for early diagnosis and disease progression monitoring
Therapeutic Compound Screening: High-throughput screening for compounds that can modulate QDPR activity
Structure-Based Drug Design: Developing targeted inhibitors or activators based on QDPR crystal structureBackground
The study of Qdpr Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [QDPR Gene](/genes/qdpr)
- [Protein Quality Control](/mechanisms/protein-quality-control-network)
- [ER Stress Response](/mechanisms/er-stress-neurodegeneration)
- [Tetrahydrobiopterin Synthesis](/mechanisms/bh4-synthesis)
- [Dopamine Biosynthesis](/mechanisms/dopamine-biosynthesis)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
External Links
- [UniProt QDPR](https://www.uniprot.org/uniprot/Q16473)
- [NCBI Protein](https://www.ncbi.nlm.nih.gov/protein/NP_001341)
- [PDB Structure](https://www.ebi.ac.uk/pdbe/entry/pdb/4MTQ)
- [Gene Ontology](http://amigo.geneontology.org/amigo/term/GO:00043507)
References
[Unknown, - Quininoid dihydropteridine reductase: structure, mechanism, and therapeutic potential (n.d.)](https://pubmed.ncbi.nlm.nih.gov/23479652/)
[Unknown, - Tetrahydrobiopterin metabolism in neurological disorders: from development to degeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28714933/)
[Unknown, - Kinetic mechanism of quinoid dihydropteridine reductase (n.d.)](https://pubmed.ncbi.nlm.nih.gov/19029079/)
[Unknown, - BH4 deficiency and neurological disorders (n.d.)](https://pubmed.ncbi.nlm.nih.gov/16597675/)
[Unknown, - Crystal structure of human QDPR with bound FAD (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25255218/)
[Unknown, - Sapropterin dihydrochloride for BH4 deficiency (n.d.)](https://pubmed.ncbi.nlm.nih.gov/20301428/)
[Unknown, - GTP cyclohydrolase and QDPR in dopa-responsive dystonia (n.d.)](https://pubmed.ncbi.nlm.nih.gov/17696096/)
[Unknown, - Oxidative stress and BH4 metabolism in Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/19897650/)
[Unknown, - Tetrahydrobiopterin in Alzheimer's disease: therapeutic implications (n.d.)](https://pubmed.ncbi.nlm.nih.gov/22159583/)
[Unknown, - BH4 deficiency in multiple system atrophy (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25432162/)
[Unknown, - Gene therapy approaches for BH4 deficiency (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29873876/)